碳-11标记咪唑[1,2- A]吡啶衍生物作为靶向癌症PI3K/mTOR的新型潜在PET探针。

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING American journal of nuclear medicine and molecular imaging Pub Date : 2023-01-01
Wenqing Liu, Wenjie Ma, Min Wang, Zhuangzhuang Wang, Shaun D Grega, Qi-Huang Zheng, Zhidong Xu
{"title":"碳-11标记咪唑[1,2- A]吡啶衍生物作为靶向癌症PI3K/mTOR的新型潜在PET探针。","authors":"Wenqing Liu,&nbsp;Wenjie Ma,&nbsp;Min Wang,&nbsp;Zhuangzhuang Wang,&nbsp;Shaun D Grega,&nbsp;Qi-Huang Zheng,&nbsp;Zhidong Xu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The PI3K/Akt/mTOR pathway is frequently dysregulated in cancer due to its central role in cell growth, survival, and proliferation. Overactivation of the PI3K/Akt/mTOR pathway may occur through varying mechanisms including mutations, gene amplification, and upstream signaling events, ultimately resulting in cancer. Therefore, PI3K/Akt/mTOR pathway has emerged as an attractive target for cancer therapy and imaging. A promising approach to inhibit this pathway involves a simultaneous inhibition of both PI3K and mTOR using a dual inhibitor. Recently, a potent dual PI3K/mTOR inhibitor, 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>7</b>), was discovered and demonstrated excellent kinase selectivity IC<sub>50</sub> (PI3K/mTOR) = 0.20/21 nM; good cellular growth inhibition IC<sub>50</sub> (HCT-116 cell) = 10 nM, modest plasma clearance, and acceptable oral bioavailability. Expanding on this discovery, here we present the synthesis of the carbon-11 labeled imidazo[1,2-<i>a</i>]pyridine derivative 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-[<sup>11</sup>C]methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<i>N</i>-[<sup>11</sup>C]<b>7</b>) as a new potential radiotracer for the biomedical imaging technique positron emission tomography (PET) imaging of PI3K/mTOR in cancer. The reference standard <b>7</b> and its <i>N</i>-demethylated precursor, 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(piperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>11</b>), were synthesized in 7 and 8 steps with 10% and 7% overall chemical yield, respectively. <i>N</i>-[<sup>11</sup>C]<b>7</b> was prepared from <b>11</b> using [<sup>11</sup>C]methyl triflate ([<sup>11</sup>C]CH<sub>3</sub>OTf) through <i>N</i>-<sup>11</sup>C-methylation and isolated by high-performance liquid chromatography (HPLC) and solid-phase extraction (SPE) formulation in 40-50% radiochemical yield decay corrected to end of bombardment (EOB) based on [<sup>11</sup>C]CO<sub>2</sub>. The radiochemical purity was > 99% and the molar activity (A<sub>m</sub>) at EOB was in the range of 296-555 GBq/µmol (n = 5).</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349286/pdf/ajnmmi0013-0095.pdf","citationCount":"0","resultStr":"{\"title\":\"A carbon-11 labeled imidazo[1,2-<i>a</i>]pyridine derivative as a new potential PET probe targeting PI3K/mTOR in cancer.\",\"authors\":\"Wenqing Liu,&nbsp;Wenjie Ma,&nbsp;Min Wang,&nbsp;Zhuangzhuang Wang,&nbsp;Shaun D Grega,&nbsp;Qi-Huang Zheng,&nbsp;Zhidong Xu\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The PI3K/Akt/mTOR pathway is frequently dysregulated in cancer due to its central role in cell growth, survival, and proliferation. Overactivation of the PI3K/Akt/mTOR pathway may occur through varying mechanisms including mutations, gene amplification, and upstream signaling events, ultimately resulting in cancer. Therefore, PI3K/Akt/mTOR pathway has emerged as an attractive target for cancer therapy and imaging. A promising approach to inhibit this pathway involves a simultaneous inhibition of both PI3K and mTOR using a dual inhibitor. Recently, a potent dual PI3K/mTOR inhibitor, 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>7</b>), was discovered and demonstrated excellent kinase selectivity IC<sub>50</sub> (PI3K/mTOR) = 0.20/21 nM; good cellular growth inhibition IC<sub>50</sub> (HCT-116 cell) = 10 nM, modest plasma clearance, and acceptable oral bioavailability. Expanding on this discovery, here we present the synthesis of the carbon-11 labeled imidazo[1,2-<i>a</i>]pyridine derivative 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(4-[<sup>11</sup>C]methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<i>N</i>-[<sup>11</sup>C]<b>7</b>) as a new potential radiotracer for the biomedical imaging technique positron emission tomography (PET) imaging of PI3K/mTOR in cancer. The reference standard <b>7</b> and its <i>N</i>-demethylated precursor, 2,4-difluoro-<i>N</i>-(2-methoxy-5-(3-(5-(2-(piperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-<i>a</i>]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (<b>11</b>), were synthesized in 7 and 8 steps with 10% and 7% overall chemical yield, respectively. <i>N</i>-[<sup>11</sup>C]<b>7</b> was prepared from <b>11</b> using [<sup>11</sup>C]methyl triflate ([<sup>11</sup>C]CH<sub>3</sub>OTf) through <i>N</i>-<sup>11</sup>C-methylation and isolated by high-performance liquid chromatography (HPLC) and solid-phase extraction (SPE) formulation in 40-50% radiochemical yield decay corrected to end of bombardment (EOB) based on [<sup>11</sup>C]CO<sub>2</sub>. The radiochemical purity was > 99% and the molar activity (A<sub>m</sub>) at EOB was in the range of 296-555 GBq/µmol (n = 5).</p>\",\"PeriodicalId\":7572,\"journal\":{\"name\":\"American journal of nuclear medicine and molecular imaging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349286/pdf/ajnmmi0013-0095.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of nuclear medicine and molecular imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

由于PI3K/Akt/mTOR通路在细胞生长、存活和增殖中的核心作用,它在癌症中经常失调。PI3K/Akt/mTOR通路的过度激活可能通过多种机制发生,包括突变、基因扩增和上游信号事件,最终导致癌症。因此,PI3K/Akt/mTOR通路已成为癌症治疗和成像的一个有吸引力的靶点。抑制这一途径的一种有希望的方法是使用双重抑制剂同时抑制PI3K和mTOR。最近,一种有效的PI3K/mTOR双抑制剂2,4-二氟- n-(2-甲氧基-5-(3-(5-(2-(4-甲基哌嗪-1-基)乙基)-1,3,4-恶二唑-2-基)咪唑[1,2-a]吡啶-6-基)吡啶-3-基)苯磺酰胺(7)被发现,并表现出良好的激酶选择性IC50 (PI3K/mTOR) = 0.20/21 nM;良好的细胞生长抑制IC50 (HCT-116细胞)= 10 nM,适度的血浆清除率,可接受的口服生物利用度。在这一发现的基础上,我们合成了碳-11标记的咪唑[1,2-a]吡啶衍生物2,4-二氟-N-(2-甲氧基-5-(3-(2-(4-[11C]甲基哌嗪-1-基)乙基)-1,3,4-恶二唑-2-基)咪唑[1,2-a]吡啶-6-基)吡啶-3-基)苯磺酰胺(N-[11C]7),作为一种新的潜在放射性示踪剂,用于生物医学成像技术正电子发射断层扫描(PET)成像癌症PI3K/mTOR。标准品7及其n-去甲基化前体2,4-二氟- n-(2-甲氧基-5-(3-(2-(哌嗪-1-基)乙基)-1,3,4-恶二唑-2-基)咪唑[1,2-a]吡啶-6-基)吡啶-3-基)苯磺酰胺(11)分别在7步和8步合成,总化学收率分别为10%和7%。以[11C]三氟化甲酯([11C]CH3OTf)为原料,通过N-11C-甲基化法制备N-[11C]7,采用高效液相色谱(HPLC)和固相萃取(SPE)配方,以[11C]CO2为原料,在40-50%的放射化学产率衰减中校正为轰击结束(EOB),分离得到N-[11C]7。放射化学纯度> 99%,在EOB处的摩尔活性(Am)在296 ~ 555 GBq/µmol之间(n = 5)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A carbon-11 labeled imidazo[1,2-a]pyridine derivative as a new potential PET probe targeting PI3K/mTOR in cancer.

The PI3K/Akt/mTOR pathway is frequently dysregulated in cancer due to its central role in cell growth, survival, and proliferation. Overactivation of the PI3K/Akt/mTOR pathway may occur through varying mechanisms including mutations, gene amplification, and upstream signaling events, ultimately resulting in cancer. Therefore, PI3K/Akt/mTOR pathway has emerged as an attractive target for cancer therapy and imaging. A promising approach to inhibit this pathway involves a simultaneous inhibition of both PI3K and mTOR using a dual inhibitor. Recently, a potent dual PI3K/mTOR inhibitor, 2,4-difluoro-N-(2-methoxy-5-(3-(5-(2-(4-methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (7), was discovered and demonstrated excellent kinase selectivity IC50 (PI3K/mTOR) = 0.20/21 nM; good cellular growth inhibition IC50 (HCT-116 cell) = 10 nM, modest plasma clearance, and acceptable oral bioavailability. Expanding on this discovery, here we present the synthesis of the carbon-11 labeled imidazo[1,2-a]pyridine derivative 2,4-difluoro-N-(2-methoxy-5-(3-(5-(2-(4-[11C]methylpiperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (N-[11C]7) as a new potential radiotracer for the biomedical imaging technique positron emission tomography (PET) imaging of PI3K/mTOR in cancer. The reference standard 7 and its N-demethylated precursor, 2,4-difluoro-N-(2-methoxy-5-(3-(5-(2-(piperazin-1-yl)ethyl)-1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide (11), were synthesized in 7 and 8 steps with 10% and 7% overall chemical yield, respectively. N-[11C]7 was prepared from 11 using [11C]methyl triflate ([11C]CH3OTf) through N-11C-methylation and isolated by high-performance liquid chromatography (HPLC) and solid-phase extraction (SPE) formulation in 40-50% radiochemical yield decay corrected to end of bombardment (EOB) based on [11C]CO2. The radiochemical purity was > 99% and the molar activity (Am) at EOB was in the range of 296-555 GBq/µmol (n = 5).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
American journal of nuclear medicine and molecular imaging
American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
自引率
4.00%
发文量
4
期刊介绍: The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.
期刊最新文献
A radioactive and fluorescent dual modality cysteine cathepsin-B activity-based probe for the detection and treatment evaluation in rheumatoid arthritis. Accurate brain pharmacokinetic parametric imaging using the blood input function extracted from the cavernous sinus. Analysis of bone single-photon emission CT/CT and diffusion-weighted MR imaging in medication-related osteonecrosis of the jaw: focusing on the correlation between standardized uptake values and apparent diffusion coefficient values. Hemodynamic characteristics of vertebrobasilar artery fenestration combined with vertebrobasilar dolichoectasia: a study based on magnetic resonance angiography. Radiomics-based model for prediction of TGF-β1 expression in head and neck squamous cell carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1